Skip To Main Content
A.D. Burden on Muck Rack

A.D. Burden

As seen in: Color Research & Application, Wiley
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with A.D.

Contact A.D., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Psoriasis, COVID‐19 and shielding

|
By G. Becher, A.D. Burden
| Wiley Online Library Verified
Commentary PDF ShareShare Linked Article: Mahil et al. Br J Dermatol 2021; https://doi.org/10.1111/bjd.19755. The COVID‐19 pandemic has presented clinicians managing immune‐mediated inflammatory diseases (IMIDs) such as psoriasis, with many challenges.
Open in Who Shared Issue with article?

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update

|
By C.H. Smith, Z.Z.N. Yiu, T. Bale, A.D. Burden
| Wiley Online Library Verified
Guideline C.H. Smith R.
Open in Who Shared Issue with article?

Secukinumab for patients failing previous tumour necrosis factor‐α inhibitor therapy: results of a randomized open‐label study (SIGNATURE)

|
By R.B. Warren, A.Y. Finlay, A.D. Burden, J.N.W.B. Barker
| Wiley
Biological therapy, particularly with tumour necrosis factor (TNF)‐α inhibitors, has revolutionized the treatment of moderate‐to‐severe chronic plaque psoriasis. However, it does not fully meet patients’ needs. Some patients fail to respond or lose response over time1, 2 and treatment strategies for these patients are unclear.
Open in Who Shared Issue with article?
See all 5 articles